Gennex Laboratories Intrinsic Value
Gennex Laboratories intrinsic value. Gennex Laboratories (GENNEX) median intrinsic value is ₹19.82 from 9 valuation models (range ₹4–₹30), vs current price ₹9.91 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Compare with GENNEX fundamental valuation to assess whether the stock is under or overvalued.
GENNEX Valuation Methods Summary — DCF, Graham Number & P/E
Gennex Laboratories intrinsic value across 9 models vs current price ₹9.91 — upside/downside and value range per method. Read GENNEX dividend track record for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹14.08 | ₹11.26 - ₹16.90 | +42.1% | EPS: ₹0.64, Sector P/E: 22x |
| Book Value Method | asset | ₹24.77 | ₹22.29 - ₹27.25 | +149.9% | Book Value/Share: ₹97.08, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹19.82 | ₹17.84 - ₹21.80 | +100.0% | Revenue/Share: ₹103.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹19.82 | ₹17.84 - ₹21.80 | +100.0% | EBITDA: ₹28.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹24.77 | ₹19.82 - ₹29.72 | +149.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹4.10 | ₹3.69 - ₹4.51 | -58.6% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹9.89 | ₹8.90 - ₹10.88 | -0.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹19.82 | ₹17.84 - ₹21.80 | +100.0% | ROE: 8.6%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹29.73 | ₹26.76 - ₹32.70 | +200.0% | EPS: ₹0.64, BVPS: ₹97.08 |
GENNEX Intrinsic Value vs Market Price — All Valuation Models
Gennex Laboratories fair value range ₹4–₹30 vs current market price ₹9.91 across 9 valuation models. For current market price and key ratios, visit Gennex Laboratories share price chart.
GENNEX Intrinsic Value Analysis — Undervalued or Overvalued?
Gennex Laboratories median intrinsic value ₹19.82, current price ₹9.91 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of GENNEX?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Gennex Laboratories (GENNEX) is ₹19.82 (median value). With the current market price of ₹9.91, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹4.10 to ₹29.73, indicating ₹4.10 - ₹29.73.
Is GENNEX undervalued or overvalued?
Based on our multi-method analysis, Gennex Laboratories (GENNEX) appears to be trading below calculated value by approximately 100.0%.
GENNEX Financial Health — Key Ratios vs Industry Benchmarks
Gennex Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 6.16 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 8.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.71x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GENNEX Cash Flow Quality — Operating & Free Cash Flow
Gennex Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-64 Cr | ₹-67 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-47 Cr | ₹-47 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹24 Cr | ₹5 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹12 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |